Trial Profile
Everolimus plus exemestane for hormone resistant metastatic breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 03 Jul 2015 New trial record
- 02 Jun 2015 23 patients were enrolled between Sep 2012 and Jan 2015, according to the 2015 ASCO abstract.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.